NPC - AXEL Study : Axitinib-Avelumab

NCT04562441 | Completed Phase 2

• 1 other identifier: NPC 033
• Study Type: interventional
• Target: 13
• Locations: 1 country
• Sites: 1

Brief Summary

Nasopharyngeal cancer (NPC) is the most common head and neck cancer in South China and South East Asia. Worldwide, there are 80,000 incident cases and 50,000 deaths annually. In Hong Kong, NPC ranked as the tenth most common cancer in man. Up to 30% of NPC patients will develop recurrence or metastases after primary radiotherapy or chemoradiation. Platinum-based chemotherapy regimen has been the main stay of first line treatment for recurrent or metastatic NPC. However, the duration of response is short and currently there is no recommended standard second line chemotherapy. Axitinib is a highly potent and selective inhibitor of VEGF receptor. Selectively targeting a single growth factor receptor pathway provides the potential to rationally adjust dosages and combine drugs directed at specific parts of the pathway to minimize toxicity and achieve the optimum therapeutic benefit. In the phase 2 axitinib monotherapy in recurrent or metastatic NPC who failed at least one line of chemotherapy, the clinical benefit rate (CBR, complete response + partial response + stable disease) was 78.4% at 3 months but decreased to 43.2% at 6 months. However, the confirmed objective response rate (ORR) by RECIST was only 2.7% and unconfirmed ORR of 18.9%, with no complete response.Recently, the promising clinical activity of immune check point inhibitors has been demonstrated in NPC. The ORR was 25.9% (7 partial responses out of 27 patients) for single agent pembrolizumab, and 20.5% (including 1 complete response and 7 partial responses out of 44 patients) for single agent nivolumab,9 in recurrent or metastatic NPC who failed at least first line chemotherapy. The combination of axitinib and avelumab has been studied in renal cell carcinoma (RCC). Based on the above promising and positive results in renal cell carcinoma (RCC) and head and neck squamous cell carcinomas (HNSCC), the investigators hypothesize that the combination of axitinib and avelumab in the second line setting of NPC will achieving a more complete, deep and durable response than either agent alone, without a significant increase in toxicity. This is an open-label, single arm, phase 2 clinical trial evaluating the activity and safety of the combination of axitinib and avelumab in recurrent or metastatic NPC patients who failed at least one line of platinum-based chemotherapy.

Conditions

Recurrent or Metastatic NPC

Outcome Measures

Primary Outcomes (1)

• Confirmed objective response rate (ORR)

  2 years

Secondary Outcomes (11)

• Progression-free survival (PFS)

  3 years

• 6-month PFS rate

  6 months

• Overall survival (OS)

  3 years

• OS rates at 12 months and 24 months

  2 years

• Objective tumor response rate

  2 years

Study Arms (1)

Axitinib and Avelumab

EXPERIMENTAL

Axitinib: 5 mg bd po Day 1 to Day 28 Avelumab: 10mg/kg Day 1 and Day 15 every 4 weeks

Drug: Axitinib; Drug: Avelumab

Interventions

Axitinib DRUG

Axitinib: 5 mg bd po Day 1 to Day 28

Axitinib and Avelumab

Avelumab DRUG

Avelumab: 10 mg/kg Day 1 to Day 15 every 4 weeks

Axitinib and Avelumab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically confirmed diagnosis of nasopharyngeal carcinoma (NPC) (either at initial diagnosis or at recurrence).
• Available fresh or archival tumor tissue for biomarker study
• Patients with recurrent or metastatic NPC that has progressed following one line of prior platinum-based chemotherapy.
• Disease must be not amenable to potentially curative radiotherapy or surgery.
• At least one measurable lesion as defined by RECIST v1.1 that has not been previously irradiated.
• Age 18 or above;
• ECOG performance 0 or 1.
• Adequate bone marrow, renal and hepatic reserve.

You may not qualify if:

• Prior therapy with immune check point inhibitors or VEGF pathway inhibitors.
• Presence of local recurrence.
• Presence of neck lymph node recurrence invading vascular structure.
• Presence of central lung lesions involving major blood vessels.
• History of hemoptysis or epistaxis within 4 weeks.
• Preexisting uncontrolled hypertension defined as more than 140/90 mmHg despite adequate medical therapy.
• Gastrointestinal abnormalities, including inability to take oral medication or malabsorption syndrome.
• Concurrent use or anticipated need for treatment with known potent CYP3A4 inhibitors or CYP3A4 /CYP1A2 inducers.
• CNS metastases requiring systemic steroid
• Active autoimmune disease
• Pregnant or lactating female

Sponsors & Collaborators

• Chinese University of Hong Kong: lead

Study Sites (1)

Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong

Hong Kong, Hong Kong

Location

MeSH Terms

Conditions

Recurrence

Interventions

Axitinib; avelumab

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Benzamides; Amides; Organic Chemicals; Benzoates; Acids, Carbocyclic; Carboxylic Acids; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Indazoles; Pyrazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Officials

• Anthony Chan, MD

  Department of Clinical Oncology, The Chinese University of Hong Kong

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director, CCTU, Department of Clinical Oncology, CUHK

Study Record Dates

• First Submitted: September 14, 2020
• First Posted: September 24, 2020
• Study Start: May 6, 2021
• Primary Completion: October 31, 2024
• Study Completion: November 7, 2024
• Last Updated: January 10, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

HK (1)